Literature DB >> 10183315

An instrument for measurement of outcomes of care for schizophrenia. Issues in development and implementation.

B J Cuffel1, E P Fischer, R R Owen, G R Smith.   

Abstract

To advance effectiveness research in mental health, we need common, standardized, validated instruments that can be used easily in routine practice settings. The Schizophrenia Outcomes Module is a relatively brief, comprehensive instrument for monitoring and assessing the outcomes of treatment for schizophrenia in clinical care settings. The module was developed with the guidance of a multiinstitutional, multidisciplinary expert panel; the clinical and theoretical considerations that framed the expert panel's deliberations and determined the module's content and characteristics are described. Initial field testing of the instrument involved longitudinal observation of 100 individuals with schizophrenia over a 6-month period. To our knowledge, it is the only brief and easily administered instrument that encompasses the four major outcome domains defined by the National Institute of Mental Health's Plan for Research on the Severely Mentally Ill. As such, it is a promising tool for effectiveness research in schizophrenia.

Entities:  

Mesh:

Year:  1997        PMID: 10183315     DOI: 10.1177/016327879702000107

Source DB:  PubMed          Journal:  Eval Health Prof        ISSN: 0163-2787            Impact factor:   2.651


  12 in total

1.  Use of electronic medical record data for quality improvement in schizophrenia treatment.

Authors:  Richard R Owen; Carol R Thrush; Dale Cannon; Kevin L Sloan; Geoff Curran; Teresa Hudson; Mark Austen; Mona Ritchie
Journal:  J Am Med Inform Assoc       Date:  2004-06-07       Impact factor: 4.497

2.  The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.

Authors:  Robert R Conley; Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Bruce J Kinon
Journal:  Schizophr Res       Date:  2006-11-15       Impact factor: 4.939

3.  Factors contributing to the quality of sibling relationships for adults with schizophrenia.

Authors:  Matthew J Smith; Jan S Greenberg
Journal:  Psychiatr Serv       Date:  2008-01       Impact factor: 3.084

4.  Comorbidity in Schizophrenia: Conceptual Issues and Clinical Management.

Authors:  Hussain Muhammad Abdullah; Hameed Azeb Shahul; Michael Y Hwang; Stephen Ferrando
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

5.  Psychological distress among latino family caregivers of adults with schizophrenia: the roles of burden and stigma.

Authors:  Sandy M Magaña; Jorge I Ramírez García; María G Hernández; Raymond Cortez
Journal:  Psychiatr Serv       Date:  2007-03       Impact factor: 3.084

6.  Prosocial family processes and the quality of life of persons with schizophrenia.

Authors:  Jan S Greenberg; Kraig J Knudsen; Kelly A Aschbrenner
Journal:  Psychiatr Serv       Date:  2006-12       Impact factor: 3.084

Review 7.  A systematic search and critical review of studies evaluating psychometric properties of patient-reported outcome measures for schizophrenia.

Authors:  Benjamin Buck; Emily C Gagen; Tate F Halverson; Arundati Nagendra; Kelsey A Ludwig; John C Fortney
Journal:  J Psychiatr Res       Date:  2021-12-27       Impact factor: 4.791

8.  Machine learning approach to measurement of criticism: The core dimension of expressed emotion.

Authors:  Arezoo Movaghar; David Page; Krishanu Saha; Moira Rynn; Jan Greenberg
Journal:  J Fam Psychol       Date:  2021-08-19

9.  Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI.

Authors:  Alexander S Young; Noosha Niv; Matthew Chinman; Lisa Dixon; Susan V Eisen; Ellen P Fischer; Jeffrey Smith; Marcia Valenstein; Stephen R Marder; Richard R Owen
Journal:  Community Ment Health J       Date:  2010-07-25

10.  Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study.

Authors:  Gebra B Cuyún Carter; Denái R Milton; Haya Ascher-Svanum; Douglas E Faries
Journal:  BMC Psychiatry       Date:  2011-08-26       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.